Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
复制标题
DOI：
10.1002/mds.26417
复制
发表时间：
2016-03
期刊：
影响因子：
--
通讯作者：
Huang X
中科院分区：
文献类型：
--
作者：
Du G;Liu T;Lewis MM;Kong L;Wang Y;Connor J;Mailman RB;Huang X
帕金森病（PD）的病理特征是黑质白质多巴胺神经元丢失和铁超载。据报道，基于磁共振成像（MRI）R2* 变化，PD患者中脑铁含量增加。由于定量磁敏感性成像是一种测量铁含量的新型MRI方法，因此我们将其与R2* 进行了比较，以评估PD的中脑变化。从47名PD患者和47名健康对照中获得定量易感性图和R2* 图。中脑易感性和R2* 值通过在标准化空间中使用基于体素和感兴趣区域的方法进行分析，并与临床数据一起进行沿着分析，包括疾病持续时间、统一帕金森病评定量表（Unified Parkinson's Disease Rating Scale，简称UMRS）I、II和III子评分以及左旋多巴等效日剂量。所有研究均在PD患者“服药”时进行。与对照组相比，PD患者的右侧（簇大小= 106 mm 3）和左侧（164 mm 3）中脑的易感性值显着增加，位于腹外侧的红核，对应于黑质部延髓。该地区的易感性值与疾病持续时间、CARS-II和左旋多巴等效日剂量显著相关。相反，R2* 仅在左侧黑质丘脑部的一个小得多的区域（62 mm 3）显著增加，与临床参数无显著相关性。定量药敏图的使用表明，与临床PD状态相关的显著黑质变化比R2* 更敏感。这些数据表明，定量磁化率映射可能是一个上级成像生物标志物R2* 估计脑铁水平在PD。
Parkinson’s disease (PD) is marked pathologically by dopamine neuron loss and iron overload in the substantia nigra pars compacta. Midbrain iron content is reported to be increased in PD based on magnetic resonance imaging (MRI) R2* changes. Because quantitative susceptibility mapping is a novel MRI approach to measure iron content, we compared it with R2* for assessing midbrain changes in PD. Quantitative susceptibility mapping and R2* maps were obtained from 47 PD patients and 47 healthy controls. Midbrain susceptibility and R2* values were analyzed by using both voxel-based and region-of-interest approaches in normalized space, and analyzed along with clinical data, including disease duration, Unified Parkinson’s Disease Rating Scale (UPDRS) I, II, and III sub-scores, and levodopa-equivalent daily dosage. All studies were done while PD patients were “on drug.” Compared with controls, PD patients showed significantly increased susceptibility values in both right (cluster size = 106 mm3) and left (164 mm3) midbrain, located ventrolateral to the red nucleus that corresponded to the substantia nigra pars compacta. Susceptibility values in this region were correlated significantly with disease duration, UPDRS II, and levodopa-equivalent daily dosage. Conversely, R2* was increased significantly only in a much smaller region (62 mm3) of the left lateral substantia nigra pars compacta and was not significantly correlated with clinical parameters. The use of quantitative susceptibility mapping demonstrated marked nigral changes that correlated with clinical PD status more sensitively than R2*. These data suggest that quantitative susceptibility mapping may be a superior imaging biomarker to R2* for estimating brain iron levels in PD.